Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. is set to unveil preliminary findings from its Phase 1b study of EP-104GI, aimed at treating eosinophilic esophagitis, at the Digestive Disease Week Annual Meeting 2024 in Washington, D.C. The study leverages Eupraxia’s proprietary DiffuSphere™ technology to enhance drug delivery, potentially offering longer-lasting effects with reduced side effects. Interest is heightened as the company’s Chief Scientific Officer, Amanda Malone, PhD, will present these significant insights.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
